What smart money is saying about Kwality Pharmaceuticals
1 fund in our archive has pitched Kwality Pharmaceuticals — most recently Seven Canyons Advisors Ark Global Emerging Companies, LP in June 2026.
Kwality Pharmaceuticals Ltd. is dedicated to developing and manufacturing a diverse range of pharmaceutical products, presented in various dosage forms. Their extensive portfolio includes items such as tablets, boluses, oral liquid medications, sterile injectable powders, topical ointments, ophthalmic solutions, capsules, liquid injectables, dry powders intended for oral suspensions, and external preparations. The enterprise was established by Ramesh Arora on May 4, 1983, and its principal operations are based in Amritsar, India.
Get an email when a fund writes about it
Position history
Every position in Kwality Pharmaceuticals on record in the archive was reported in Q2 2026, across 1 fund letter — 1 opened or added to the position.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 1 | 0 | 1 |
Fund activity · 1 position · 1 move
- AddedSeven Canyons Advisors Ark Global Emerging Companies, LPJune 2026
“Kwality Pharmaceuticals (KWPL IN) makes generic formulations in nearly every dosage form, from injectables to oral solids, and exports them to dozens of markets. The quality shows up in the numbers: a non-cash return on assets of almost 21% and a return on equity of 23% - each improving in every quarter over the last two years. The March quarter was the company's best ever (outside the COVID years), with sales up 36% and earnings up 75%. The stock has risen more than 50% since results were published May 19th. That re-rating places the shares at roughly 43x trailing earnings - no longer the sub-20x P/E bargain we paid upon initiating the position. Kwality was our favorite company from last year's India trip, and we moved accordingly - first purchasing shares December 9th and building the position above a 6% weight by late February after the company posted strong Q3 results.”
Read the letterKwality Pharmaceuticals
Fund coverage · 1 thesis
- Seven Canyons Advisors Ark Global Emerging Companies, LPJune 2026
Kwality Pharmaceuticals makes generic formulations and exports them globally, with high ROA/ROE, strong growth, and a still-attractive forward PEG supporting a multi-year compounding thesis.
Read the full thesis
Read every full thesis on Kwality Pharmaceuticals
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→